Chromosomal abnormalities associated with local recurrence or pulmonary metastasis of giant cell tumor of bone in Thai adults: a prospective cohort study with 6 years of follow-up
Keywords:Chromosomal abnormalities, pulmonary metastasis, giant cell tumor of bone, Thai adults, local recurrence, gene
Background: Giant cell tumor (GCT) of bone demonstrates chromosomal abnormalities. This study aimed to investigate the prognostic role of chromosomal abnormalities of primary GCT of bone relative to local recurrence or pulmonary metastasis.
Methods: This prospective longitudinal cohort study with 6 years of follow-up included consecutive patients with primary GCT of bone that were surgically treated during 2011 to 2013 at the Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. All patients underwent surgical resection with extended intralesional curettage and phenol local adjuvant therapy. Systematic cytogenetic analysis compared cytogenetic abnormalities between patients with and without local recurrence or pulmonary metastasis. Fifteen patients were eligible, enrolled, and had successful cytogenetic analysis.
Results: The median follow-up time was 46 months (interquartile range [IQR]: 32-58). Five patients experienced local recurrence or pulmonary metastasis with a median time to recurrence of 6 months (IQR: 3.25-10.5). The mean number of abnormal cells in the primary culture compared between those with local recurrence or pulmonary metastasis and those without was 24.4 vs. 9.6 cells, respectively (p=0.04). A similar pattern was observed in the cultures of the subsequent four passages (all p<0.05). Forty-five patterns of clonal telomeric association (tas) were observed in passaged cultures. Six tas patterns were associated with local recurrence or pulmonary metastasis, including tas(11;19)(p15;q13.4), tas(15;19)(q26.3;q13.4), tas(15;22)(p13;p13), tas(16;19)(p13.3;q13.4), tas(17;19)(p13;q13.4), and tas(19;22)(q13.4;q13).
Conclusions: The mean number of abnormal cells and the six identified TAS patterns may be valuable prognostic factors for local recurrence or pulmonary metastasis of GCT tumor of bone.
Pongkripetch M, Sirikulchayanonta V. 1989. Analysis of bone tumors in Ramathibodi Hospital, Thailand during 1977-1986: study of 652 cases. J Med Assoc Thai 72: 621-628.
Settakorn J, Lekawanvijit S, Arpornchayanon O, et al. 2006. Spectrum of bone tumors in Chiang Mai University Hospital, Thailand according to WHO classification 2002: A study of 1,001 cases. J Med Assoc Thai 89: 780-787.
Liede A, Hernandez RK, Tang ET, Li C, Bennett B, Wong SS, Jandial D. Epidemiology of benign giant cell tumor of bone in the Chinese population. J Bone Oncol. 2018 Jul 26;12:96-100.
Cao H, Lin F, Hu Y, et al. 2017. Epidemiological and Clinical Features of Primary Giant Cell Tumors of the Distal Radium: A Multicenter Retrospective Study in China. Sci Rep 7: 9067.
Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S, Rimondi E, Rossi G, Longhi A, Mercuri M. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev. 2010 Feb;36(1):1-7.
Karpik M. Giant Cell Tumor (tumor gigantocellularis, osteoclastoma) - epidemiology, diagnosis, treatment. Ortop Traumatol Rehabil. 2010 May-Jun;12(3):207-15.
Klenke, F. M., Wenger, D. E., Inwards, C. Y., Rose, P. S. & Sim, F. H. Giant cell tumor of bone: risk factors for recurrence. Clin Onhop Relat Res. 469, 591–599 (2011).
Hasan O, Ali M, Mustafa M, Ali A, Umer M. Treatment and recurrence of giant cell tumors of bone - A retrospective cohort from a developing country. Ann Med Surg (Lond). 2019;48:29‐34.
Robinson D, Yassin M, Nevo Z. 2004. Cryotherapy of musculoskeletal tumors--from basic science to clinical results. Technol Cancer Res Treat 3: 371-375.
van der Heijden L, van der Geest IC, Schreuder HW, et al. 2014. Liquid nitrogen or phenolization for giant cell tumor of bone?: a comparative cohort study of various standard treatments at two tertiary referral centers. J Bone Joint Surg Am 96: e35.
Chen KH, Wu PK, Chen CF, et al. 2015. Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage. Eur Spine J 24: 2182-2188.
Waikakul S, Asavamongkolkul A, Phimolsarnti R. 2016. Use of warm Ringer's lactate solution in the management of locally advanced giant cell tumor of bone. Int J Clin Oncol 21: 177-185.
Campanacci M, Baldini N, Boriani S, et al. 1987. Giant-cell tumor of bone. J Bone Joint Surg Am 69: 106-114.
Rousseau MA, Handra-Luca A, Lazennec JY, et al. 2004. Metachronous multicentric giant-cell tumor of the bone in the lower limb. Case report and Ki-67 immunohistochemistry study. Virchows Arch 445: 79-82.
Balke M, Schremper L, Gebert C, et al. 2008. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 134: 969-978.
Gupta R, Seethalakshmi V, Jambhekar NA, et al. 2008. Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India. Ann Diagn Pathol 12: 239-248.
Ismail FW, Shamsudin AM, Wan Z, et al. 2010. Ki-67 immuno-histochemistry index in stage III giant cell tumor of the bone. J Exp Clin Cancer Res 29: 25.
Chanchairujira K, Jiranantanakorn T, Phimolsarnti R, et al. 2011. Factors of local recurrence of giant cell tumor of long bone after treatment: plain radiographs, pathology and surgical procedures. J Med Assoc Thai 94: 1230-1237.
He Y, Wang J, Zhang J, et al. 2017. A prospective study on predicting local recurrence of giant cell tumour of bone by evaluating preoperative imaging features of the tumour around the knee joint. Radiol Med 122: 546-555.
Papanastassiou I, Ioannou M, Papagelopoulos PJ, et al. 2010. P53 expression as a prognostic marker in giant cell tumor of bone: a pilot study. Orthopedics 33.
Saito T, Mitomi H, Suehara Y, et al. 2011. A case of de novo secondary malignant giant-cell tumor of bone with loss of heterozygosity of p53 gene that transformed within a short-term follow-up. Pathol Res Pract 207: 664-669.
Okubo T, Saito T, Mitomi H, et al. 2013. p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1. Virchows Arch 463: 67-77.
Zhang K, Zhou M, Chen H, et al. 2015. Expression of IMP3 and IGF2 in giant cell tumor of spine is associated with tumor recurrence and angiogenesis. Clin Transl Oncol 17: 570-575.
Bridge JA, Neff JR, Bhatia PS, et al. 1990. Cytogenetic findings and biologic behavior of giant cell tumors of bone. Cancer 65: 2697-2703.
atcc.org [Internet]. Manassas: American Type Culture Collection; Technical Bulletin no.6, Reference Strains: How many passages are too many? [Updated 2014 Mar 27; cited 2020 Nov 20]
Bertoni F, Present D, Sudanese A, et al. 1988. Giant-cell tumor of bone with pulmonary metastases. Six case reports and a review of the literature. Clin Orthop Relat Res: 275-285.
Cheng JC, Johnston JO. 1997. Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases. Clin Orthop Relat Res: 205-214.
Dominkus M, Ruggieri P, Bertoni F, et al. 2006. Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. Int Orthop 30: 499-504.
Errani C, Ruggieri P, Asenzio MA, et al. 2010. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 36: 1-7.
Klenke FM, Wenger DE, Inwards CY, et al. 2011. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 469: 591-599.
Gorunova L, Vult von Steyern F, Storlazzi CT, et al. 2009. Cytogenetic analysis of 101 giant cell tumors of bone: nonrandom patterns of telomeric associations and other structural aberrations. Genes Chromosomes Cancer 48: 583-602.
Zheng MH, Siu P, Papadimitriou JM, et al. 1999. Telomeric fusion is a major cytogenetic aberration of giant cell tumors of bone. Pathology 31: 373-378.
Garcia JL, Robledo C, Lumbreras E, et al. 2006. Analysis of chromosomal imbalances in an elderly woman with a giant cell tumour. Virchows Arch 448: 95-99.
Forsyth RG, De Boeck G, Bekaert S, et al. 2008. Telomere biology in giant cell tumour of bone. J Pathol 214: 555-563.
Sawyer JR, Goosen LS, Binz RL, et al. 2005. Evidence for telomeric fusions as a mechanism for recurring structural aberrations of chromosome 11 in giant cell tumor of bone. Cancer Genet Cytogenet 159: 32-36.
Unni KK. 1996. Dahlin’s bone tumor: general aspect and data on 11,087 cases. 5th ed. Philadelphia: Lippincott-Raven.
- 2022-05-21 (3)
- 2022-05-22 (1)
How to Cite
Copyright (c) 2022 Journal of Medical Globalization
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.